GLSI
Greenwich LifeSciences, Inc.
Price Chart
Latest Quote
$23.03
-0.72 (-3.03%)
Current Price
| Previous Close | $23.75 |
| Open | $23.66 |
| Day High | $23.99 |
| Day Low | $22.91 |
| Volume | 67,808 |
Stock Information
| Shares Outstanding | 14.68M |
| Cash Equivalents | $10.51M |
| Net Income | $-22.27M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $338.04M |
| EPS (TTM) | $-1.61 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $327.53M |
| Income | $-22.27M |
| Book/sh | $0.36 |
| Cash/sh | $0.72 |
Financial Ratios
| Quick Ratio | 2.01 |
| Current Ratio | 2.01 |
Returns & Margins
| ROA | -211.27% |
| ROE | -676.66% |
Ownership
| Insider Ownership | 47.86% |
| Institutional Ownership | 12.42% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -28.09 |
| P/B | 64.15 |
Analyst Data
| Recommendation | none |
| Target Price | $47.50 |
Technical Indicators
| SMA20 | $24.47 |
| SMA50 | $24.72 |
| SMA200 | $19.33 |
| RSI | 42.34 |
| ATR | 1.6671 |
| Shares Float | 7.39M |
| Short Float | 19.84% |
| Short Ratio | 11.85 |
| Volatility | 1.38 |
| Rel Volume | 0.50 |
Performance History
| Week | -1.62% |
| Month | -15.30% |
| Quarter | -8.72% |
| 6 Months | +85.88% |
| YTD | +18.28% |
| Year | +158.76% |
| 3 Years | +108.61% |
| 5 Years | -42.03% |
| 10 Years | +360.60% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $23.03 | 72,000 |
| 2026-06-22 | $23.75 | 87,000 |
| 2026-06-18 | $23.38 | 92,500 |
| 2026-06-17 | $23.99 | 110,700 |
| 2026-06-16 | $23.88 | 132,800 |
| 2026-06-15 | $23.41 | 59,600 |
| 2026-06-12 | $24.06 | 94,500 |
| 2026-06-11 | $23.03 | 55,500 |
| 2026-06-10 | $22.11 | 64,600 |
| 2026-06-09 | $22.23 | 85,900 |
| 2026-06-08 | $21.65 | 170,100 |
| 2026-06-05 | $22.25 | 179,900 |
| 2026-06-04 | $23.67 | 271,900 |
| 2026-06-03 | $24.29 | 124,200 |
| 2026-06-02 | $24.29 | 487,500 |
| 2026-06-01 | $28.51 | 224,600 |
| 2026-05-29 | $26.17 | 190,300 |
| 2026-05-28 | $28.99 | 106,100 |
| 2026-05-27 | $29.23 | 177,100 |
| 2026-05-26 | $27.39 | 99,200 |
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
đ° Latest News
GLSI Stock Climbs After Removing A Key Overhang â Retail Turns Focus To High-Stakes Breast Cancer Trial
Stocktwits âĸ 2026-06-01T11:48:52Z
Insiders of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) must be frustrated after market cap dropped US$50m since recent purchases
Simply Wall St. âĸ 2026-01-23T14:35:16Z
Sector Update: Health Care Stocks Mixed Late Afternoon
MT Newswires âĸ 2026-01-22T20:54:59ZTop Midday Gainers
MT Newswires âĸ 2026-01-22T18:58:08ZWall Street Set to Open Higher Thursday as Investors Parse GDP, Unemployment Data, Look Ahead to Inflation Report
MT Newswires âĸ 2026-01-22T14:25:55ZInvestors Await Raft of Key Economic Data as US Futures Rise Thursday Pre-Bell
MT Newswires âĸ 2026-01-22T13:13:26ZGreenwich LifeSciences Gets FDA Approval for GP2 for Breast Cancer Recurrence Trial
MT Newswires âĸ 2026-01-22T11:59:27ZSeveral Insiders Invested In Greenwich LifeSciences Flagging Positive News
Simply Wall St. âĸ 2025-11-14T10:43:12Z
Owning 53% in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) means that insiders are heavily invested in the company's future
Simply Wall St. âĸ 2025-08-16T14:00:12Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $19,447,918 | $17,637,227 | $9,327,866 | $8,040,254 |
| Net Non Operating Interest Income Expense | $89,700 | $223,008 | $436,063 | $215,017 |
| Operating Expense | $19,447,918 | $17,637,227 | $9,327,866 | $8,040,254 |
| General And Administrative Expense | $2,227,517 | $2,157,010 | $1,629,244 | $1,564,586 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-19,358,218 | $-17,414,219 | $-8,891,803 | $-7,825,237 |
| Net Interest Income | $89,700 | $223,008 | $436,063 | $215,017 |
| Interest Income | $89,700 | $223,008 | $436,063 | $215,017 |
| Normalized Income | $-19,358,218 | $-17,414,219 | $-8,891,803 | $-7,825,237 |
| Net Income From Continuing And Discontinued Operation | $-19,358,218 | $-17,414,219 | $-8,891,803 | $-7,825,237 |
| Total Operating Income As Reported | $-19,447,918 | $-17,637,227 | $-9,327,866 | $-8,040,254 |
| Net Income Common Stockholders | $-19,358,218 | $-17,414,219 | $-8,891,803 | $-7,825,237 |
| Net Income | $-19,358,218 | $-17,414,219 | $-8,891,803 | $-7,825,237 |
| Net Income Including Noncontrolling Interests | $-19,358,218 | $-17,414,219 | $-8,891,803 | $-7,825,237 |
| Net Income Continuous Operations | $-19,358,218 | $-17,414,219 | $-8,891,803 | $-7,825,237 |
| Pretax Income | $-19,358,218 | $-17,414,219 | $-8,891,803 | $-7,825,237 |
| Interest Income Non Operating | $89,700 | $223,008 | $436,063 | $215,017 |
| Operating Income | $-19,447,918 | $-17,637,227 | $-9,327,866 | $-8,040,254 |
| Per Share | ||||
| Diluted EPS | $-1.43 | $-1.34 | $-0.69 | $-0.61 |
| Basic EPS | $-1.43 | $-1.34 | $-0.69 | $-0.61 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-19,446,139 | $-17,633,615 | $-9,324,254 | $-8,036,642 |
| Reconciled Depreciation | $1,779 | $3,612 | $3,612 | $3,612 |
| EBITDA (Bullshit earnings) | $-19,446,139 | $-17,633,615 | $-9,324,254 | $-8,036,642 |
| EBIT | $-19,447,918 | $-17,637,227 | $-9,327,866 | $-8,040,254 |
| Diluted Average Shares | $13,534,994 | $13,014,585 | $12,848,165 | $12,913,848 |
| Basic Average Shares | $13,534,994 | $13,014,585 | $12,848,165 | $12,913,848 |
| Diluted NI Availto Com Stockholders | $-19,358,218 | $-17,414,219 | $-8,891,803 | $-7,825,237 |
| Research And Development | $17,220,401 | $15,480,217 | $7,698,622 | $6,475,668 |
| Selling General And Administration | $2,227,517 | $2,157,010 | $1,629,244 | $1,564,586 |
| Other Gand A | $2,227,517 | $2,157,010 | $1,629,244 | $1,564,586 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $353,217 | $906,847 | $6,695,018 | $13,205,121 |
| Total Assets | $6,178,021 | $4,093,769 | $6,994,815 | $13,477,029 |
| Total Non Current Assets | $0 | $1,779 | $5,391 | $9,003 |
| Goodwill And Other Intangible Assets | $0 | $1,779 | $5,391 | $9,003 |
| Current Assets | $6,178,021 | $4,091,990 | $6,989,424 | $13,468,026 |
| Cash Cash Equivalents And Short Term Investments | $6,178,021 | $4,091,990 | $6,989,424 | $13,468,026 |
| Cash And Cash Equivalents | $6,178,021 | $4,091,990 | $6,989,424 | $13,468,026 |
| Cash Financial | $6,178,021 | $4,091,990 | $6,989,424 | $13,468,026 |
| Other Intangible Assets | - | $1,779 | $5,391 | $9,003 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,824,804 | $3,185,143 | $294,406 | $262,905 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $5,824,804 | $3,185,143 | $294,406 | $262,905 |
| Current Deferred Liabilities | $673,819 | $306,281 | - | - |
| Payables And Accrued Expenses | $5,150,985 | $2,878,862 | $294,406 | $262,905 |
| Payables | $4,874,489 | $2,802,946 | $256,317 | $220,845 |
| Accounts Payable | $4,874,489 | $2,802,946 | $256,317 | $220,845 |
| Interest Payable | - | - | - | $220,845 |
| Equity | ||||
| Common Stock Equity | $353,217 | $908,626 | $6,700,409 | $13,214,124 |
| Total Equity Gross Minority Interest | $353,217 | $908,626 | $6,700,409 | $13,214,124 |
| Stockholders Equity | $353,217 | $908,626 | $6,700,409 | $13,214,124 |
| Retained Earnings | $-87,137,006 | $-67,778,788 | $-50,364,569 | $-41,472,766 |
| Other | ||||
| Ordinary Shares Number | $14,298,446 | $13,152,729 | $12,848,165 | $12,848,165 |
| Share Issued | $14,298,446 | $13,152,729 | $12,848,165 | $12,848,165 |
| Tangible Book Value | $353,217 | $906,847 | $6,695,018 | $13,205,121 |
| Invested Capital | $353,217 | $908,626 | $6,700,409 | $13,214,124 |
| Working Capital | $353,217 | $906,847 | $6,695,018 | $13,205,121 |
| Total Capitalization | $353,217 | $908,626 | $6,700,409 | $13,214,124 |
| Additional Paid In Capital | $87,475,924 | $68,674,261 | $57,052,130 | $54,674,042 |
| Capital Stock | $14,299 | $13,153 | $12,848 | $12,848 |
| Common Stock | $14,299 | $13,153 | $12,848 | $12,848 |
| Current Accrued Expenses | $276,496 | $75,916 | $38,089 | $42,060 |
| Dueto Related Parties Current | - | - | - | - |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-9,913,453 | $-7,266,543 | $-6,478,602 | $-6,200,027 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,913,453 | $-7,266,543 | $-6,478,602 | $-6,200,027 |
| Cash Flow From Continuing Operating Activities | $-9,913,453 | $-7,266,543 | $-6,478,602 | $-6,200,027 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $11,854,484 | $4,369,109 | $0 | - |
| Financing Cash Flow | $11,999,484 | $4,369,109 | $0 | $-7,536,216 |
| Cash Flow From Continuing Financing Activities | $11,999,484 | $4,369,109 | $0 | $-7,536,216 |
| Net Common Stock Issuance | $11,854,484 | $4,369,109 | $0 | $-7,536,216 |
| Common Stock Issuance | $11,854,484 | $4,369,109 | $0 | - |
| Repurchase Of Capital Stock | - | - | $0 | $-7,536,216 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| End Cash Position | $6,178,021 | $4,091,990 | $6,989,424 | $13,468,026 |
| Beginning Cash Position | $4,091,990 | $6,989,424 | $13,468,026 | $27,204,269 |
| Changes In Cash | $2,086,031 | $-2,897,434 | $-6,478,602 | $-13,736,243 |
| Proceeds From Stock Option Exercised | $145,000 | $0 | - | $0 |
| Change In Working Capital | $2,639,661 | $2,890,737 | $31,501 | $-122,267 |
| Change In Other Working Capital | $367,538 | $306,281 | - | - |
| Change In Payables And Accrued Expense | $2,272,123 | $2,584,456 | $31,501 | $-122,267 |
| Change In Accrued Expense | $200,580 | $37,827 | $-3,971 | $-122,267 |
| Change In Payable | $2,071,543 | $2,546,629 | $35,472 | - |
| Change In Account Payable | $2,071,543 | $2,546,629 | $35,472 | $0 |
| Stock Based Compensation | $6,803,325 | $7,253,327 | $2,378,088 | $1,743,865 |
| Depreciation Amortization Depletion | $1,779 | $3,612 | $3,612 | $3,612 |
| Depreciation And Amortization | $1,779 | $3,612 | $3,612 | $3,612 |
| Amortization Cash Flow | $1,779 | $3,612 | $3,612 | $3,612 |
| Amortization Of Intangibles | $1,779 | $3,612 | $3,612 | $3,612 |
| Net Income From Continuing Operations | $-19,358,218 | $-17,414,219 | $-8,891,803 | $-7,825,237 |
| Common Stock Payments | - | - | $0 | $-7,536,216 |
| Change In Interest Payable | - | - | - | $0 |
Fetched: 2026-06-16